BCL2L11 and non-small cell lung carcinoma: In this meta-analysis, we found that individuals with mutant EGFR NSCLC harbored BIM deletion polymorphism were inferior response to TKI than did patients with BIM wild polymorphism, suggesting that BIM deletion polymorphism was inverse correlated with clinical efficacy of TKI therapy and it might be a genetic cause mediating intrinsic resistance to TKI treatment in mutant EGFR NSCLC individuals.